<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>siRNA and DsiRNA Transfection Efficiency via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'siRNA and DsiRNA Transfection Efficiency' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=siRNA+and+DsiRNA+Transfection+Efficiency&t=siRNA+and+DsiRNA+Transfection+Efficiency&s=Search&f=source]]></link>
        <lastBuildDate>Sat, 20 Mar 2010 16:33:19 +0100</lastBuildDate>
        <item>
            <title>i-Fect and More Knockdown Success</title>
            <link>http://www.medworm.com/index.php?rid=3287514&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2010%2F02%2Fi-fect-and-more-knockdown-success.html</link>
            <description>In this study researchers showed specific knockdown of CaV1.2 in the spinal dorsal horn reversed the neuropathy-associated mechanical hypersensitivity and the hyperexcitability and increased responsiveness of dorsal horn neurons. Intrathecal application of anti-CaV1.2 siRNAs confirmed the preceding results.Here's a link to the related pub: Pascal Fossat, Eric Dobremez, Rabia Bouali-Benazzouz, Alexandre Favereaux, Sandrine S. Bertrand, Kalle Kilk, Claire Léger, Jean-René Cazalets, Ülo Langel, Marc Landry and Frédéric Nagy. Knockdown of L Calcium Channel Subtypes: Differential Effects in Neuropathic Pain. The Journal of Neuroscience, January 20, 2010, 30(3):1073-1085; doi:10.1523/JNEUROSCI.3145-09.2010We used siRNA targeting several splice variants of CaV1.2 (&quot;Silencer Select Pre-design...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3287514</comments>
            <pubDate>Thu, 18 Feb 2010 18:14:00 +0100</pubDate>
            <guid isPermaLink="false">3287514</guid>        </item>
        <item>
            <title>Delivering siRNA in Mice for Studying Opioid-Induced Hyperalgesia</title>
            <link>http://www.medworm.com/index.php?rid=3153163&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2010%2F01%2Fdelivering-sirna-in-mice-for-studying.html</link>
            <description>Researchers have successfully delivered siRNA in-vitro and in-vivo using Neuromics' i-Fect ™ siRNA Transfection Reagent. Gene expression studies include: DOR, hTERT, The β3 subunit of the Na+,K+-ATPase, rSNSR1, NTS1. NAV1.8 and more.Here's a link to all transfection publications: Transfection Kit PubsWe are pleased to present yet another study and related publication. This includes one of the first successful delivery of siRNA in mice using i-Fect ™ :Yan Chen, Cheng Yang, and Zaijie Jim Wang. Ca2+/Calmodulin-Dependent Protein Kinase II Is Required for the Initiation and Maintenance of Opioid-Induced Hyperalgesia. The Journal of Neuroscience, January 6, 2010, 30(1):38-46; doi:10.1523/JNEUROSCI.4346-09.2010....KN93 and KN92 were administered intrathecally by percutaneous puncture throug...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3153163</comments>
            <pubDate>Thu, 07 Jan 2010 17:18:00 +0100</pubDate>
            <guid isPermaLink="false">3153163</guid>        </item>
        <item>
            <title>Using i-Fect for treatment of Glioblastomas</title>
            <link>http://www.medworm.com/index.php?rid=3047938&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2009%2F12%2Fusing-i-fect-for-treatment-of.html</link>
            <description>Conclusions: Our study showed that the combination of hTERT siRNA and IFN-γ effectively inhibited angiogenesis and tumor progression through the downregulation of molecules involved in these processes. Therefore, the combination of hTERT siRNA and IFN-γ is a promising therapeutic strategy for controlling the growth of human glioblastoma. (Source: siRNA and DsiRNA Transfection Efficiency)</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3047938</comments>
            <pubDate>Tue, 01 Dec 2009 22:14:00 +0100</pubDate>
            <guid isPermaLink="false">3047938</guid>        </item>
        <item>
            <title>Delivering 27mer DsiRNAs to Mice DRGs</title>
            <link>http://www.medworm.com/index.php?rid=2508326&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2009%2F06%2Fdelivering-27mer-dsirnas-to-mice-drgs.html</link>
            <description>I have been a proponent of using 27mer DsiRNAs (Dicer Substrate Small Interfering RNAs) with our i-Fect kits to deliver siRNA to the CNS for gene expression analysis. The potency of this platform was highlighted in my profile of Dr. Mark Behlke.It was further confirmed by in Studies conducted by Dr. Philippe Serrat and his team at University of Sherbrooke.Louis Doré-Savard, Geneviève Roussy, Marc-André Dansereau, Michael A Collingwood, Kim A Lennox, Scott D Rose, Nicolas Beaudet, Mark A Behlke and Philippe Sarret. Central Delivery of Dicer-substrate siRNA: A Direct Application for Pain Research. Molecular Therapy (2008); Jul;16(7):1331-9. Epub 2008 Jun 3 doi:10.1038/mt.2008.98.Using ultra low dose of DsiRNAs complexed with Neuromics’ i-Fect , they were able to successfully reduce NTS2...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2508326</comments>
            <pubDate>Tue, 23 Jun 2009 15:39:00 +0100</pubDate>
            <guid isPermaLink="false">2508326</guid>        </item>
        <item>
            <title>Knockdown of rSNSR1 in vivo</title>
            <link>http://www.medworm.com/index.php?rid=2347272&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2009%2F04%2Fknockdown-of-rsnsr1-in-vivo.html</link>
            <description>The parade of success with use our i-FectTM in vivo grows. Here's the most recent study:Christian Ndong, Amynah Pradhan, Carole Puma, Jean-Pierre Morello, Cyrla Hoffert, Thierry Groblewski , Dajan O’Donnell, Jennifer M.A. Laird. Role of rat sensory neuron-specific receptor (rSNSR1) in inflammatory pain: Contribution of TRPV1 to SNSR signaling in the pain pathway. PAIN 143 (2009) 130–137....For experiments in which siRNA was delivered by bolus injections, 10 ul of siRNA or vehicle was injected directly into the intrathecal catheter once daily for 4 days. In this case, siRNAs were prepared immediately prior to administration by mixing the RNA solution (200 uM in annealing buffer) with the transfection reagent i-FectTM (Neuromics) at a ratio of 1:4 (w:v) for a final siRNA/ lipid complex c...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2347272</comments>
            <pubDate>Mon, 20 Apr 2009 15:12:00 +0100</pubDate>
            <guid isPermaLink="false">2347272</guid>        </item>
        <item>
            <title>Did Your RNAi Experiment Work?</title>
            <link>http://www.medworm.com/index.php?rid=2330128&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2009%2F04%2Fdid-your-rnai-experiment-work.html</link>
            <description>This is a good methods publication on RNAi transfection: Reliably Validating RNA Interference with qRT-PCR.Bill Wang, Song Tian, Qiong Zhou, and Xiao Zeng. SA Biosciences. (Source: siRNA and DsiRNA Transfection Efficiency)</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2330128</comments>
            <pubDate>Mon, 06 Apr 2009 14:37:00 +0100</pubDate>
            <guid isPermaLink="false">2330128</guid>        </item>
        <item>
            <title>Intrathecal Delivery of siRNA</title>
            <link>http://www.medworm.com/index.php?rid=2042597&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F12%2Fintrathecal-delivery-of-sirna.html</link>
            <description>We wanted to present yet another publication referencing successful delivery of siRNA using i-FectTM:Suneeta Tumati, Tally Largent Milnes, Henry I. Yamamura, Todd W. Vanderah, William R. Roeske and Eva V. Varga. Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia. doi:10.1016/j.ejphar.2008.10.033...siRNAs stock solutions (100 μM) were prepared in double distilled RNAse free water and stored in aliquots at −80 °C. For intrathecal treatment, aliquots of the stock solution (2 μg of the appropriate siRNA) were mixed (1:5 v/v)with i-Fect transfection reagent (Neuromics, Edina, MN). After recovery from the surgery (5–7 days), the animals received intrathecal injections (2 ug siRNA/10 ul/rat) of either a lipid encapsulated Raf-1-selective siRNA mix...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2042597</comments>
            <pubDate>Tue, 16 Dec 2008 19:44:00 +0100</pubDate>
            <guid isPermaLink="false">2042597</guid>        </item>
        <item>
            <title>Delivering Naked siRNA by Direct Injection</title>
            <link>http://www.medworm.com/index.php?rid=1926872&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F11%2Fdelivering-naked-sirna-by-direct.html</link>
            <description>In this study, they delivered chemically modified murine and human alpha-synuclein (SNCA) siRNAs to the hippocampus by direct injection resulting in silencing of gene expression.To learn more access:In vivo silencing of alpha-synuclein using naked siRNA Jada Lewis, Heather Melrose, David Bumcrot, Andrew Hope, Cynthia Zehr, Sarah Lincoln, Adam Braithwaite, Zhen He, Sina Ogholikhan, Kelly Hinkle, Caroline Kent, Ivanka Toudjarska, Klaus Charisse, Ravi Braich, Rajendra K. Pandey, Michael Heckman, Demetrius M Maraganore, Julia Crook, Matthew J Farrer. Molecular Neurodegeneration 2008, 3:19 (1 November 2008). (Source: siRNA and DsiRNA Transfection Efficiency)</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1926872</comments>
            <pubDate>Sun, 02 Nov 2008 15:00:00 +0100</pubDate>
            <guid isPermaLink="false">1926872</guid>        </item>
        <item>
            <title>ACIC3 Receptors Knockdown in vivo</title>
            <link>http://www.medworm.com/index.php?rid=1889287&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F10%2Facic3-receptors-knockdown-in-vivo.html</link>
            <description>In this study, Dr. Eric Lingueglia and his team found Peripheral ASIC3 channels are thus essential sensors of acidic pain and integrators of molecular signals produced during inflammation where they contribute to primary hyperalgesia.Emmanuel Deval, Jacques Noël, Nadège Lay, Abdelkrim Alloui, Sylvie Diochot, Valérie Friend, Martine Jodar, Michel Lazdunski and Eric Lingueglia. ASIC3, a sensor of acidic and primary inflammatory pain. The EMBO Journal advance online publication 16 October 2008; doi: 10.1038/emboj.2008.213Cy3-labelled siRNA no. 1121 and its corresponding scramble (no. 1121S; GCTCACACTACGCAGAGAT) synthesized by MWG Biotech (Germany) were injected in rats by intrathecal bolus to the lumbar region of the spinal cord once a day for 3 days before the induction of inflammation wi...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1889287</comments>
            <pubDate>Sun, 19 Oct 2008 19:10:00 +0100</pubDate>
            <guid isPermaLink="false">1889287</guid>        </item>
        <item>
            <title>siRNA-mediated gene silencing</title>
            <link>http://www.medworm.com/index.php?rid=1851825&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F10%2Fsirna-mediated-gene-silencing.html</link>
            <description>Dr. Josephine Lai (Professor of Pharmacology, University of Arizona) is pioneer in developing experimental designs and methods for delivering siRNA to the CNS for gene expression analysis.She and her team have documented these in the publication:Modulating Sensory Systems Using RNAi(pdf - 187Kb)© 2007 LaiFor researchers desiring to effectively deliver siRNA to the CNS for gene expression analysis of specific receptors, this publication offers proven methods. These include:The Choice of siRNA Choosing and Optimizing Transfection Reagents for siRNA Delivery to the Nervous SystemDelivery Systems-Microinjection and Infusion (using mini-osmotic pumps)Validation We will continue to track advances by Dr. Lai and team. (Source: siRNA and DsiRNA Transfection Efficiency)</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1851825</comments>
            <pubDate>Sat, 04 Oct 2008 14:08:00 +0100</pubDate>
            <guid isPermaLink="false">1851825</guid>        </item>
        <item>
            <title>Transfecting Sympathetic Neurons</title>
            <link>http://www.medworm.com/index.php?rid=1740469&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F08%2Ftransfecting-primary-neurons.html</link>
            <description>GDNF and Ret are important to the growth, maintenance and survival of Neurons. The GDNF ligands act via activation of Ret. Every step towards understanding the intricacies of this pathway, brings researchers closer towards unlocking the code for Neurodegenerative Disease therapies.siRNA is an important tool for studying the Neurotrophic pathways as researchers can use it to modulate the expression of related receptors. The tricky part is getting sufficient siRNA into neurons to do the appropriate studies of how modulating targeted genes results in changes in protein expression.Here Drs. Cynthia Tsui and Brian Pierchala have published results from there studies of C2AP and Cbl-3/Cbl-c and Ret Transduction. One of the keys to this study was using siRNA to silence CD2AP and Cbl-3 expression. ...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1740469</comments>
            <pubDate>Thu, 28 Aug 2008 21:50:00 +0100</pubDate>
            <guid isPermaLink="false">1740469</guid>        </item>
        <item>
            <title>Down Regulating the Smad and Neuro-regeneration</title>
            <link>http://www.medworm.com/index.php?rid=1730898&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F08%2Fdown-regulating-smad-and-neuro.html</link>
            <description>The inventors down regulated Smad 2/3 (an inhibitor of neuro-regeneration) in vivo via delivery of siRNA to the spinal cord using catheters.Inhibiting smad signaling promotes neuron regeneration. Inventors: Fan Wang, Zhigang HeUSPTO Application #: 20080031911Inhibition of Smad2/3 Signaling Promotes Axonal Regeneration after Spinal Injury in Rats-Gene Expression Knockdown in vivo!One hour after the spinal cord is lesioned, the rats in the SB-505124 group receive a bolus injection of SB-505124 (30 mg/kg) in 0.9% saline administered via a tail vein. The treatment is repeated every 24 hours on days 1 through 7 post-lesion. Vehicle only control rats undergo the same treatment but are injected with an equal volume of 0.09% saline in a tail vein. At the same treatment time points as the SB-505124...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1730898</comments>
            <pubDate>Mon, 25 Aug 2008 05:51:00 +0100</pubDate>
            <guid isPermaLink="false">1730898</guid>        </item>
        <item>
            <title>siRNA and Diabetes</title>
            <link>http://www.medworm.com/index.php?rid=1672506&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F07%2Fsirna-and-diabetes.html</link>
            <description>I'll be keeping my eyes on this and post updates.Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic MClinical Program Leverages Quark's RNAi Technology FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics,... (Source: siRNA and DsiRNA Transfection Efficiency)</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1672506</comments>
            <pubDate>Fri, 01 Aug 2008 01:19:00 +0100</pubDate>
            <guid isPermaLink="false">1672506</guid>        </item>
        <item>
            <title>Improving 27mer DsiRNA Performance</title>
            <link>http://www.medworm.com/index.php?rid=1650297&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F07%2Fimproving-27mer-dsirna-preformance.html</link>
            <description>The DsiRNA story marches forward with yet another important publication. We will give you an opportunity to upload the fulltext article at the end of this posting. Dr. Mark Behlke, Dr John Rossi and team have been gaining deeper understanding of the Mechanism of Dicer-substrate small-interfering RNA (DsiRNA) processing. This understanding is leading to better and better designs of the RNA duplexes. These designs or chemical modifications are necessary steps in the drug design and development process. This publication looks at design from the perspective of: Nuclease StabilityPharmacokinecticsimmune response I believe this is an important publication for researchers wanting to better understand: The mechanisms behind successful delivery of DsiRNA for gene expression studies.Variations in po...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650297</comments>
            <pubDate>Mon, 21 Jul 2008 02:53:00 +0100</pubDate>
            <guid isPermaLink="false">1650297</guid>        </item>
        <item>
            <title>Coming Soon</title>
            <link>http://www.medworm.com/index.php?rid=1650298&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F07%2Fcoming-soon.html</link>
            <description>Agenda Topics:Target Discovery and ValidationTransfectionsiRNA Therapeuticsin vivo RNAi-recent in vivo RNAi PubsBioinformatics of small RNAssiRNA library screensmicroRNAs inDisease Biology:Stem Cell BiologyDiagnosticsVirologyBiogenesisDevelopment (Source: siRNA and DsiRNA Transfection Efficiency)</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650298</comments>
            <pubDate>Tue, 08 Jul 2008 14:20:00 +0100</pubDate>
            <guid isPermaLink="false">1650298</guid>        </item>
        <item>
            <title>RNAi Researchers Galvanized by Advances</title>
            <link>http://www.medworm.com/index.php?rid=1650299&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F06%2Frnai-researchers-galvanized-by-advances.html</link>
            <description>Technology's Viability in Drug Development Is Finally EstablishedAuthor: Elizabeth LippPublication: Genetic Engineering &amp; biotechnology NewsPublisher: Mary Ann Liebert, Inc. publishersDate: Jun 1, 2008Copyright © 2008 GEN PublishingArticle Link: http://www.genengnews.com/articles/chitem.aspx?aid=2493Notable Quotables:“Long dsRNAs have been employed for many years as a means to modulate gene expression in plants, yeast, and C. elegans,” noted Mark Behlke, M.D., Ph.D., svp of molecular genetics and CSO at Integrated DNA Technologies (IDT; www.idtdna.com).“Similar attempts in higher organisms failed due to interferon activation, however we now know that short RNA duplexes can be safely used in mammalian systems both in vitro and in vivo. The technology has rapidly matured, thanks i...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650299</comments>
            <pubDate>Wed, 18 Jun 2008 14:33:00 +0100</pubDate>
            <guid isPermaLink="false">1650299</guid>        </item>
        <item>
            <title>Hi Thru Put Delivery of siRNA/DsiRNA</title>
            <link>http://www.medworm.com/index.php?rid=1650300&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F06%2Fhi-thru-put-delivery-of-sirnadsirna.html</link>
            <description>NEW PRODUCTi-Fect ™ Hi Put 96-NewLearn about transfection products @ neuromics (Source: siRNA and DsiRNA Transfection Efficiency)</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650300</comments>
            <pubDate>Mon, 16 Jun 2008 14:58:00 +0100</pubDate>
            <guid isPermaLink="false">1650300</guid>        </item>
        <item>
            <title>Central Delivery of DsiRNA</title>
            <link>http://www.medworm.com/index.php?rid=1650301&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F06%2Fcentral-delivery-of-dsirna.html</link>
            <description>Louis Doré-Savard, Geneviève Roussy, Marc-André Dansereau, Michael A Collingwood, Kim A Lennox, Scott D Rose, Nicolas Beaudet, Mark A Behlke and Philippe Sarret. Central Delivery of Dicer-substrate siRNA: A Direct Application for Pain Research. Molecular Therapy (2008); doi:10.1038/mt.2008.98.Images: Cellular uptake of Texas Red–tagged Dicer-substrate small-interfering RNA (DsiRNA) by spinal nociceptive structures. (a,b) Distribution of fluorescence in lumbar dorsal root ganglia at 24 hours after intrathecal injection of a control siRNA conjugated with Texas Red (1 μg administered twice with a 24-hour interval; n = 3). As seen by confocal microscopy, the staining is not uniformly distributed among the cells. Higher-magnification images also show that the fluorescent signal is detecte...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650301</comments>
            <pubDate>Wed, 04 Jun 2008 19:53:00 +0100</pubDate>
            <guid isPermaLink="false">1650301</guid>        </item>
        <item>
            <title>Ret Knockdown Using Small Interference RNA</title>
            <link>http://www.medworm.com/index.php?rid=1650302&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2008%2F04%2Fret-knockdown-using-small-interference.html</link>
            <description>Nearly 100% Transfection Efficiency Reported in vitro with i-Fect ™.Images: Ret receptor knockdown using small interference RNA (siRNA) in podocytes. (A) Transfection efficiency: mouse podocytes were transfected with 100 nM concentrations of Ret siRNA or vehicle alone. (a) When podocytes were exposed to i-Fect alone, there was no toxicity. (a and b) A transfection efficiency of nearly 100% was achieved with 100 nM concentration of Ret siRNA (b). Co-transfection with a fluorescently tagged control siRNA was used to determine the transfection efficiency, and fluorescence microscopy revealed a perinuclear localization of the tagged RNA (b, arrowhead). (B) Western blot analysis of Ret after transfection: Ret immunoblotting (top) of WCL 2, 3, or 4 d after transfection revealed that Ret was do...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650302</comments>
            <pubDate>Wed, 09 Apr 2008 15:30:00 +0100</pubDate>
            <guid isPermaLink="false">1650302</guid>        </item>
        <item>
            <title>RNAi therapeutics: a potential new class of pharmaceutical drugs</title>
            <link>http://www.medworm.com/index.php?rid=1650303&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2007%2F11%2Frnai-therapeutics-potential-new-class.html</link>
            <description>Comprehensive and Cogent overview on delivery methods:David Bumcrot1, Muthiah Manoharan1, Victor Koteliansky1 and Dinah W Y Sah1. RNAi therapeutics: a potential new class of pharmaceutical drugsNature Chemical Biology 2, 711-719 (2006) doi:10.1038/nchembio839 (Source: siRNA and DsiRNA Transfection Efficiency)</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650303</comments>
            <pubDate>Mon, 26 Nov 2007 17:27:00 +0100</pubDate>
            <guid isPermaLink="false">1650303</guid>        </item>
        <item>
            <title>i-Fect and Posters @ SfN</title>
            <link>http://www.medworm.com/index.php?rid=1650304&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2007%2F11%2Fi-fect-and-posters-sfn.html</link>
            <description>This study is supported by NIH grant R01NS046785.Disclosures: M. Luo , None; D. Zhang, None; E. Zhang, None; Q. Chen, None; P. Ge, None; D. Sah, None; T. Vanderah, None; F. Porreca, None; J. Lai, None.Support:NIH grant R01NS046785[Authors]. [Abstract Title]. Program No. XXX.XX. 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2007. Online.Program#/Poster#:509.6/PP9Title:Small interfering RNA-mediated selective knockdown of NTS2 receptors reverses neurotensin-induced analgesia in ratsLocation:San Diego Convention Center: Halls B-HPresentation Start/End Time:Monday, Nov 05, 2007, 2:00 PM - 3:00 PMAuthors:*L. DORE-SAVARD1,2, G. ROUSSY1, M.-A. DANSEREAU1, K. BELLEVILLE1, N. BEAUDET1, M. BEHLKE2, P. SARRET1; 1Physiology and Biophysics, Univ. Sherbrooke, Sherbrooke, PQ...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650304</comments>
            <pubDate>Thu, 08 Nov 2007 01:44:00 +0100</pubDate>
            <guid isPermaLink="false">1650304</guid>        </item>
        <item>
            <title>More on Delivering siRNA in vivo</title>
            <link>http://www.medworm.com/index.php?rid=1650305&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2007%2F10%2Fmore-on-delivering-sirna-in-vivo.html</link>
            <description>We are excited about this upcoming presentation at Society for Neuroscience comference presesentation. Neuromics' i-Fect ™ reagent was used to deliver siRNA in vivo to silence the NTS2 gene.Program#/Poster#:509.6/PP9Title:Small interfering RNA-mediated selective knockdown of NTS2 receptors reverses neurotensin-induced analgesia in ratsLocation:San Diego Convention Center: Halls B-HPresentation Start/End Time:Monday, Nov 05, 2007, 2:00 PM - 3:00 PMAuthors:*L. DORE-SAVARD1,2, G. ROUSSY1, M.-A. DANSEREAU1, K. BELLEVILLE1, N. BEAUDET1, M. BEHLKE2, P. SARRET1;1Physiology and Biophysics, Univ. Sherbrooke, Sherbrooke, PQ, Canada; 2Integrated DNA Technologies Inc., Coralville, IA2007Copyright by the Society for Neuroscience all rights reserved. Permission to republish any abstract or part of any...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650305</comments>
            <pubDate>Tue, 30 Oct 2007 12:29:00 +0100</pubDate>
            <guid isPermaLink="false">1650305</guid>        </item>
        <item>
            <title>i-Fect and Nav1.8 Gene Silencing in vivo</title>
            <link>http://www.medworm.com/index.php?rid=1650306&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2007%2F05%2Fi-fect-and-silencing-nav18-gene.html</link>
            <description>Referenced in United States Patent 20070105806Link to patent: Free Patents Online[0241] The effect of siRNAs against Nav1.8, formulated with iFECT, on complete Freund's adjuvant-induced tactile hypersensitivity was evaluated in rats (FIG. 5). Adult male Sprague-Dawley rats received an injection of CFA (150 uL) into the hindpaw on day 0. siRNAs against Nav1.8 were then administered by intrathecal bolus to the lumbar region of the spinal cord on days 1, 2 and 3; specifically, for each bolus injection, 2 ug of siRNA was complexed with iFECT transfection reagent (Neuromics, Minneapolis Minn., USA) at a ratio of 1:4 (w:v) in a total volume of 10 uL. Five groups of rats (with 5 rats per group) were treated with either siRNA (AL-DP-6049, AL-DP-6209, AL-DP-6217 or AL-DP-6218; Table 1), or PBS, in ...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650306</comments>
            <pubDate>Wed, 23 May 2007 00:07:00 +0100</pubDate>
            <guid isPermaLink="false">1650306</guid>        </item>
        <item>
            <title>Magnetically Enhanced siRNA Transfection</title>
            <link>http://www.medworm.com/index.php?rid=1650307&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2007%2F04%2Fincreasing-sirna-transfection.html</link>
            <description>We have added a new set of products that magnetically drive transfection.MATra products are designed to enhance the transfection capabilties of our i-Fect and pn-Fect kits.The technique requires lease or purchase of the Universal Magnetic Plate AND for i-Fect and other siRNA transfection reagents, please also purchase the MATra-siRNA Reagent. For pn-Fect and other Nucleic Acid transfectants, you would buy the MATra-A Regeant.If your cells are in suspension, you will also need MATra-s-Immobilizer.Manual for All MATra ProductsMATra FAQsMagnet Assisted Transfection AnimationReferences:Publications:Bertram, J. (2006) MATra - Magnet Assisted Transfection: Combining Nanotechnology and Magnetic Forces to Improve Intracellular Delivery of Nucleic Acids. Current Pharmaceutical Biotechnology 7, 277-...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650307</comments>
            <pubDate>Mon, 02 Apr 2007 23:44:00 +0100</pubDate>
            <guid isPermaLink="false">1650307</guid>        </item>
        <item>
            <title>Duration of siRNA studies-pain study example</title>
            <link>http://www.medworm.com/index.php?rid=1650308&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2007%2F02%2Fduration-of-sirna-studies-pain-study.html</link>
            <description>We are working with an investigator on using RNAi to relieve pain and his study prompted some discussion about the length of time before an effect is seen. It is important to note that these types of experiments take time to see an effect. In studying the pain response, the effect may take even longer.  Dorn et al (Nucleic Acids Res. 2004 Mar 16;32) examined the ability of siRNA to relieve chronic neuropathic pain targeting P2X3 in vivo. They showed a significant effect on the ability of the siRNA to relieve the pain; however there was no significant effect until around 6 days post.    Another study by Hemmings-Mieszczak et al (Nucleic Acids Research, 2003, Vol. 31, No. 8 2117-2126) showed that in an in vitro model, oligofectamine-mediated transfection of siRNA resulted in 60±90% downregu...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650308</comments>
            <pubDate>Wed, 07 Feb 2007 04:07:00 +0100</pubDate>
            <guid isPermaLink="false">1650308</guid>        </item>
        <item>
            <title>Transfecting Primary Cells</title>
            <link>http://www.medworm.com/index.php?rid=1650309&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2007%2F01%2Ftransfecting-primary-cells.html</link>
            <description>We welcome any comments on you experiences with transfecting primary cell lines with cationic lipids and/or electroporation.Here're are interesting comments of transfecting primary cells from Dr. Mark Behlke, CSO of IDT:&quot;Just wanted to give you a project update. We have good transfection conditions worked out for LTK cells and CHO cells now. Different reagents and different conditions proved to be optimal for each cell line.The LTK cells proved to be a real nightmare. We were testing out different siRNAs and had a weird problem that it seemed that none of the siRNA worked even a little, with the weird observation that our controls were “very low”. After quite a bit of investigation, we finally figured out that the LTK cells were triggering an IFN pathway response to the siRNAs. Unfortu...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650309</comments>
            <pubDate>Mon, 15 Jan 2007 19:18:00 +0100</pubDate>
            <guid isPermaLink="false">1650309</guid>        </item>
        <item>
            <title>Protocols for Delivering siRNA to Neurons</title>
            <link>http://www.medworm.com/index.php?rid=1650310&amp;cid=s_37786_168_f&amp;fid=37786&amp;url=http%3A%2F%2Fsirnatransfection.blogspot.com%2F2007%2F01%2Fprotocols-for-delivering-sirna-to.html</link>
            <description>Here's a link to the protocol: Transfecting Schwann Cells with i-Fect and below are related data. Figure:si RNA-mediated suppression of target gene expression in Schwann cells. A, Detergent extracts of siNeg- or siGly1- transfected Schwann cells were digested with heparitinase and subjected to immunoblot analysis with anti-glypican-1 antibodies (top);aliquots of undigested extracts wereimmunoblotted with anti-actin antibodies (bottom) to verify equal sample loading. B, Cell surface expression of glypican-1 was assessed by immunofluorescent staining of transfected cells 48 h after transfection using anti-glypican- 1 antibodies (green) and DAPI (4',6'-diamidino-2 phenylindole) to stain nuclei (red). C, Schwann cells were transfected with siNeg or si 4(V)and conditioned media and cell lysates...</description>
            <author>siRNA and DsiRNA Transfection Efficiency</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1650310</comments>
            <pubDate>Fri, 12 Jan 2007 22:33:00 +0100</pubDate>
            <guid isPermaLink="false">1650310</guid>        </item>
    </channel>
</rss>
